Drug guidance
Febuxostat for treating chronic hyperuricaemia in adults with gout
Condition
Blood and Immune System
Liver
2 May 2019
Published on 02 May 2019
Last Updated on 02 May 2019
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing febuxostat on the Medication Assistance Fund (MAF) for treating chronic hyperuricaemia in adults with gout because of unacceptable cost-effectiveness compared with alternative treatments at the price proposed by the manufacturer.
Febuxostat for chronic hyperuricaemia in adults with gout (2 May 2019) [PDF, 464 KB]